Phosphodiesterase 10A enzyme (PDE10A) is an important striatal target that has been shown to be affected in patients with neurodegenerative disorders, particularly Huntington´s disease (HD). PDE10A is expressed on striatal neurones in basal ganglia where other known molecular targets are enriched such as dopamine D receptors (D R). The aim of this study was to examine the availability of PDE10A enzyme in relation with age and gender and to compare those changes with those related to D R and volumes in different regions of the basal ganglia. As a secondary objective we examined the relative distribution of D R and PDE10A enzyme in the striatum and globus pallidus. Forty control subjects (20F/20M; age: 44±11y, age range 27-69) from an ongoing positron emission tomography (PET) study in HD gene expansion carriers were included. Subjects were examined with PET using the high-resolution research tomograph (HRRT) and with 3T magnetic resonance imaging (MRI). The PDE10A radioligand F-MNI-659 and D R radioligand C-raclopride were used. The outcome measure was the binding potential (BP) estimated with the two-tissue compartment model (F-MNI-659) and the simplified reference tissue model (C-raclopride) using the cerebellum as reference region. The PET data were corrected for partial volume effects. In the striatum, PDE10A availability showed a significant age-related decline that was larger compared to the age-related decline of D R availability and to the age-related decline of volumes measured with MRI. In the globus pallidus, a less pronounced decline of PDE10A availability was observed, whereas D R availability and volumes seemed to be rather stable with aging. The distribution of the PDE10A enzyme was different from the distribution of D R, with higher availability in the globus pallidus. These results indicate that aging is associated with a considerable physiological reduction of the availability of PDE10A enzyme in the striatum. Moreover as result of the analysis, in the striatum for both the molecular targets, we observed a gender effect with higher BP the female group.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroimage.2017.02.047DOI Listing

Publication Analysis

Top Keywords

pde10a enzyme
16
basal ganglia
12
globus pallidus
12
age-related decline
12
pde10a
9
dopamine receptors
8
pet study
8
partial volume
8
molecular targets
8
availability pde10a
8

Similar Publications

Phosphodiesterase 2 A (PDE2A) function is stimulated by cGMP to catabolize cAMP. However, neurological and neurochemical effects of PDE2A deficiency are poorly understood. To address this gap, we studied behavioral characteristics and cerebral morpho-chemical changes of adult male heterozygous C57BL/6-PDE2A+/- (HET), and wild type C57BL/6-PDE2A+/+ (WT) mice.

View Article and Find Full Text PDF

Inhibition of Phosphodiesterase 10A Alleviates Pain-like Behavior in Mice.

Anesthesiology

February 2025

Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, Frankfurt am Main, Germany.

Background: Emerging evidence indicates that cyclic nucleotide phosphodiesterases exert distinct functions in pain processing and that targeting phosphodiesterases might be a novel strategy for pain relief. This study hypothesized that the phosphodiesterase isoform phosphodiesterase 10A (PDE10A) might be a target for analgesic therapy.

Methods: In situ hybridization, immunostaining, cyclic nucleotide enzyme immunoassays, real-time cyclic guanosine monophosphate imaging, and real-time quantitative reverse transcription polymerase chain reaction were performed to investigate the expression and activity of PDE10A in the dorsal root ganglia and spinal cord.

View Article and Find Full Text PDF
Article Synopsis
  • MK-8189 is a new PDE10A inhibitor being studied as a potential treatment for schizophrenia, showing strong effectiveness in increasing important signaling molecules in the brain.
  • In animal studies, MK-8189 significantly reduced avoidance behavior and reversed cognitive deficits related to schizophrenia, indicating its potential for improving symptoms associated with the disorder.
  • Research on MK-8189 has helped inform dose selection for clinical trials by establishing a link between its effectiveness and the level of PDE10A engagement in the brain.
View Article and Find Full Text PDF

Inhibition of phosphodiesterase 10A mitigates neuronal injury by modulating apoptotic pathways in cold-induced traumatic brain injury.

Mol Cell Neurosci

December 2024

Department of Physiology, School of Medicine, Istanbul Medeniyet University, Istanbul, Türkiye; Regenerative and Restorative Medical Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Türkiye.

Brain injury develops from a complex series of pathophysiological phases, resulting in acute necrotic or delayed apoptotic cell death after traumatic brain injury (TBI). Inhibition of apoptotic cell death is critical for the treatment of acute neurodegenerative disorders, such as TBI. Here, we investigated the role of phosphodiesterase 10A (PDE10A) in the development of neuronal injury, particularly in apoptotic cell death.

View Article and Find Full Text PDF

Schizophrenia (SCZ) is a complex neuropsychiatric disorder characterized by positive, negative, and cognitive symptoms. The neurodevelopmental methylazoxy-methanol acetate (MAM) rodent model replicates key neurobiological features of SCZ which includes hyperdopaminergic states in the ventral tegmental area (VTA) and cognitive deficits. Typical and atypical antipsychotics are primarily effective in treating the positive symptoms of SCZ but often fall short of addressing cognitive deficits.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!